Key Points
- CEO Daniel Barber sold 8,257 shares of Aquestive Therapeutics at an average price of $4.29, totaling about $35,422.53. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still directly owns 660,574 shares.
- Q1 earnings beat expectations: Aquestive reported a loss of $0.07 per share, better than the expected loss of $0.14, and revenue of $14.45 million versus estimates of $10.90 million.
- Analysts remain cautiously positive on AQST, with an average rating of “Buy” and a consensus price target of $8.80. The stock was trading around $4.14, well below that target.
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) CEO Daniel Barber sold 8,257 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $4.29, for a total value of $35,422.53. Following the transaction, the chief executive officer directly owned 660,574 shares of the company's stock, valued at approximately $2,833,862.46. This trade represents a 1.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Barber also recently made the following trade(s):
- On Tuesday, March 10th, Daniel Barber sold 180,677 shares of Aquestive Therapeutics stock. The stock was sold at an average price of $4.17, for a total value of $753,423.09.
Aquestive Therapeutics Stock Down 0.7%
NASDAQ:AQST opened at $4.14 on Tuesday. Aquestive Therapeutics, Inc. has a twelve month low of $2.22 and a twelve month high of $7.55. The business has a 50 day moving average price of $4.16 and a two-hundred day moving average price of $4.74. The company has a market cap of $519.36 million, a P/E ratio of -6.79 and a beta of 1.50.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.07. The firm had revenue of $14.45 million for the quarter, compared to analyst estimates of $10.90 million. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aquestive Therapeutics
Several large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC acquired a new stake in Aquestive Therapeutics during the 3rd quarter valued at $28,000. BNP Paribas Financial Markets lifted its holdings in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after purchasing an additional 4,134 shares during the last quarter. Lineweaver Wealth Advisors LLC acquired a new stake in Aquestive Therapeutics during the 4th quarter valued at $65,000. ADAR1 Capital Management LLC lifted its holdings in Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company's stock valued at $42,000 after purchasing an additional 264,000 shares during the last quarter. Finally, Modern Wealth Management LLC acquired a new stake in Aquestive Therapeutics during the 2nd quarter valued at $33,000. Institutional investors and hedge funds own 32.45% of the company's stock.
Analyst Ratings Changes
AQST has been the subject of several recent analyst reports. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a report on Tuesday, February 3rd. Oppenheimer initiated coverage on Aquestive Therapeutics in a report on Friday, April 24th. They issued an "outperform" rating and a $8.00 price objective for the company. Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aquestive Therapeutics presently has an average rating of "Buy" and an average target price of $8.80.
View Our Latest Analysis on AQST
Aquestive Therapeutics Company Profile
(
Get Free Report)
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
